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Abstract
Folate deficiency is implicated in the causation of neural tube defects (NTDs). The preventive effect of periconceptional folic
acid supplement use is partially explained by the treatment of a deranged folate-dependent one carbon metabolism, which
provides methyl groups for DNA-methylation as an epigenetic mechanism. Here, we hypothesize that variations in DNA-
methylation of genes implicated in the development of NTDs and embryonic growth are part of the underlying mechanism.
In 48 children with a neural tube defect and 62 controls from a Dutch case-control study and 34 children with a neural tube
defect and 78 controls from a Texan case-control study, we measured the DNA-methylation levels of imprinted candidate
genes (IGF2-DMR, H19, KCNQ1OT1) and non-imprinted genes (the LEKR/CCNL gene region associated with birth weight, and
MTHFR and VANGL1 associated with NTD). We used the MassARRAY EpiTYPER assay from Sequenom for the assessment of
DNA-methylation. Linear mixed model analysis was used to estimate associations between DNA-methylation levels of the
genes and a neural tube defect. In the Dutch study group, but not in the Texan study group we found a significant
association between the risk of having an NTD and DNA methylation levels of MTHFR (absolute decrease in methylation of
20.33% in cases, P-value = 0.001), and LEKR/CCNL (absolute increase in methylation: 1.36% in cases, P-value = 0.048), and a
borderline significant association for VANGL (absolute increase in methylation: 0.17% in cases, P-value = 0.063). Only the
association between MTHFR and NTD-risk remained significant after multiple testing correction. The associations in the
Dutch study were not replicated in the Texan study. We conclude that the associations between NTDs and the methylation
of the MTHFR gene, and maybe VANGL and LEKKR/CNNL, are in line with previous studies showing polymorphisms in the
same genes in association with NTDs and embryonic development, respectively.
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Introduction
Neural tube defects (NTDs) are congenital malformations
accompanied with low birth weight, which result from a failure
of the neural tube to close during the fourth week of embryogen-
esis. The most common phenotypes of NTDs are spina bifida and
anencephaly [1]. Interactions between environmental exposures
and subtle variations in genes are thought to be involved in
the pathogenesis of NTD. A maternal folate shortage during the
sensitive period of neural tube development contributes to the
development of NTD, and the occurrence of the disease can be
reduced by periconceptional maternal folic acid supplement use
[2]. However, the mechanisms underlying this relationship are not
completely understood.
Epigenetic alterations can cause changes in gene expression that
are not directly related to the DNA sequence itself, of which DNA-
methylation is one of the best understood epigenetic mechanisms
[2]. DNA-methylation of genes is rather stable throughout life,
except for example in the periconception period. It is an important
mechanism in epigenetic programming of tissues, organ develop-
ment and functioning. To establish DNA-methylation, DNA
methyltransferases use methyl donors such as folate derived from
the one carbon metabolism (1-C metabolism) essential during the
periconceptional period [3]. Therefore, a reduced availability of
methyl donors can lead to DNA hypomethylation with conse-
quences for epigenetic programming. Several substrates like folate
and cofactors such as vitamin B12 are implicated in 1C-
metabolism. The 1C-metabolism has repeatedly been associated
with DNA-methylation [4,5]. Maternal vitamin B12 deficiency has
been associated with an increased risk for NTD [6–10], linking
maternal 1-C metabolism to closure of the neural tube in the
developing child.
Higher DNA-methylation levels of IGF2 DMR have been
reported in children of mothers taking periconceptional folic
acid in supplements [11]. High maternal homocysteine levels
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are associated with NTDs in the offspring [12] and with
genome-wide hypo DNA-methylation in umbilical cord blood
cells [13,14]. In addition, vitamin B12 has also been suggested
to influence DNA-methylation in umbilical cord blood cells
[15]. Moreover, genetic variants in key genes that are involved
in the 1C-metabolism are related to changes in DNA-
methylation. Common variants of the MTHFR gene
(c.677C.T and c.1298A.C) can result in a reduction of
enzymatic activity [16,17], which together with a low folate and
or vitamin B12 status can result in elevated homocysteine levels
and global DNA hypomethylation [18–20].
These MTHFR polymorphisms have been well studied in
associations with NTD [16,17]. Animal studies suggest that DNA-
methylation is implicated in neural tube closure [21,22], indicating
that changes in DNA-methylation could influence the risk for
NTD. Recently, it was shown by Chang et al. that maternal serum
folate was lower in NTD cases compared to controls, and that the
maternal serum folate levels were correlated with methylated
cytosines in the brain of NTD fetuses [23]. A previous study
reported hypomethylation of the DNA-repair gene MGMT in
brain tissue of NTD cases [24]. Global hypomethylation was also
found to be association with NTD in brain tissue [25] as was
LINE1 hypomethylation [26]. From this background, we hypoth-
esize that derangements in DNA-methylation of (non)imprinted
genes implicated in embryonic and neural tube development
contribute to NTD risk. In two cohorts of NTD cases and controls,
we studied associations between DNA-methylation levels in fetuses
and very young children using a candidate gene approach of
imprinted candidate genes (IGF2, H19, and KCNQ1OT1) and non-
imprinted LEKR/CCNL gene region involved in embryonic
development and MTHFR, and VANGL1 that are associated with
NTDs.
Methods
Study Design and Data Collection
Dutch case-control study. Between August 1999 and
December 2001, a case-control triad study was conducted in
which mothers of a child with a non-syndromatic meningo(my-
elo)cele, i.e., spina bifida, were enrolled in collaboration with the
Dutch Spina Bifida Teams of the University Medical Centers of
Nijmegen, Utrecht, Groningen, Rotterdam, Leiden, Amsterdam,
and the regional hospitals in Tilburg and Zwolle in The
Netherlands. Dutch Caucasian women and their children between
1 and 3 years of age were eligible to participate. The spina bifida
was diagnosed by a neuropediatrician at birth. Control subjects
were recruited from acquaintances and nurseries in Nijmegen and
surroundings in the Netherlands as described in detail previously
[6,27]. Written informed consent was obtained from the parents of
the children. The informed consent and study protocol was
approved by the Institutional Review Board of the University
Medical Center Nijmegen, the Netherlands.
The original study population comprised 63 mothers and 70
children with spina bifida and 102 control mothers and 85
children. In the present study we selected 48 case and 62 control
children with available high quality DNA derived from pher-
ipheral white blood cells. For standardized research data collection
parents and their children visited the outpatient clinic of the
University Medical Center Nijmegen, the Netherlands. Mothers
filled out questionnaires concerning demographic data and lifestyle
factors in the periconceptional period (3 months before until 3
months after conception) of the pregnancy and at the moment of
blood sampling [3]. Maternal body weight and length were
measured to calculate the body mass index (BMI, kg/m2). During
the visit 2 ml of maternal venous blood and 1 ml of venous blood
of the child were drawn to measure concentrations of red blood
cell (RBC) and serum folate, serum vitamin B12 and plasma total
homocysteine (tHcy) and handled as described previously [6].
Maternal blood samples were drawn after an overnight fast.
Children’s white blood cell genomic DNA was extracted from
whole blood according to standard procedures [28].
Texan case-control study. Study subjects were recruited
from a Mexican American population from the 14 counties along
the Texas-Mexico border region that terminated their pregnancies
or delivered between 1995 and 2000. Cases were terminations
(spontaneous or selective abortions), livebirths, or stillbirths with
any diagnosis of NTD, defined as spina bifida or anencephaly.
They were identified through hospitals, birth centers, ultrasound
centers, abortion centers, prenatal clinics, genetics clinics, and
birth attendants (midwives and non-hospital physicians). Controls
were non-malformed live births that occurred in the same counties
during that time period. Subjects were approached about study
enrollment either prenatally or in the hospital at the time of
delivery or pregnancy termination. Interviews were scheduled
approximately 1 month postpartum. Before the interview, written
informed consent was obtained from both parents of the subject in
the parent’s preferred language. The protocol, consent forms, and
questionnaire were approved by the Texas Department of Health
institutional review board for the protection of human subjects
[29]. The study protocol was reviewed and approved by the Texas
A&M University System Health Science Center Internal Review
Board (IRB) and the Department of State Health Services
(formerly Texas Department of Health) IRB. Participant identi-
fication and data collection have been described in detail
elsewhere [9,30,31].
In the present study 34 cases and 78 control children were
included. Women were interviewed at home using a standard
instrument modeled after the Centers for Disease Control and
Prevention’s 1993 mother questionnaire for birth defects risk
factor surveillance. With this instrument, information was
obtained on maternal age at conception, years of schooling,
maternal folic acid supplement use and smoking habits during the
periconceptional period (from 3 months before to 3 months after
conception). BMI was calculated from self-reported pre-pregnancy
height and weight. During the interview, maternal blood samples
were drawn to measure concentrations of red blood cell (RBC) and
serum folate, and serum vitamin B12 and handled as described
previously [9].
Genomic DNA was extracted from 5 2.5 mm dried blood spots
(Guthriepaper) using the Quickgene SP DNA tissue kit (Fujifilm)
according to the manufacturers protocol. Isolated DNA was stored
at 220uC.
Quantitative Assessment of DNA-methylation
The amplicons for IGF2-DMR, H19 were described previously
[32]. Amplicons for KCNQOT1, MTHFR, VANGL1 and LEKR/
CCNL were designed using the EpiDesigner tool (Sequenom,
Inc, San Diego, USA). The three imprinted genes are IGF2-
DMR, H19 and KCNQOT1, which are involved in embryonic
growth and development. The three non-imprinted genes are
MTHFR, VANGL1 and LEKR/CCNL. MTHFR is involved in 1-
C metabolism and the 677C.T and 1298A.C polymorphisms
in this gene as well as mutations in VANGL1 are associated with
the risk of NTD [16,17,33–35]. We also selected the candidate
gene-region LEKR/CCNL. A polymorphism in the same LD-
block as the CpG-island in this region is associated with
birthweight, a marker often used for prenatal growth [36],
Amplicons for IGF2-DMR and H19 were taken from the study
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by Heijmans et al [37]. Table S1 shows the location, length and
primers of the amplicons. First, the amplicons were tested on a
standard curve constructed from DNA with low and high
methylation (EpigenDx, Worcester, MA, USA) in steps of 10%
methylation difference. Only amplicons with a good distribution
of the methylation percentages were used for the measurements
of the samples. In Figure S1 the locations of the CpG-islands
studied with respect to the genes are depicted.
Isolated genomic DNA (500 ng) was treated with sodium
bisulphite for 16 hours using the EZ-96 DNA-methylation kit
(Shallow) (Zymo Research, Irvine, CA, USA). This was followed
by PCR amplification, fragmentation after reverse transcription
and analysis on a mass spectrometer (Sequenom, Inc, San Diego,
USA). This generated mass signal patterns that were translated
into quantitative DNA-methylation levels of different CpG sites of
earlier mentioned genes in all tissues by MassARRAY EpiTYPER
Analyzer software (v1.0, build1.0.6.88 Sequenom, Inc, San Diego,
USA) [38]. Fragments containing one or more CpG sites were
called CpG units. Measurements were done in triplicate on DNA
from the same bisulfite-treatment batch on different PCR-plates.
On every bisulphite plate, standard DNA with low methylation,
25%, 50%, 75% and high methylation was included. This
standard DNA was used to check the technical steps of the
experiment.
Data Cleaning
During quality control CpG units with a too low or too high
mass or CpG unitswith overlapping RNA fragments were
excluded from further analysis. Furthermore, two out of three of
the replicate measurements per CpG unit had to be successful, and
the SD of the duplicates or triplicates had to be #0.10. Outliers
per CpG (.3SD) were excluded from further analysis, CpG units
with interference of SNP’s were also excluded. Bisulfite conversion
was assessed using the MassArray R package [39], which uses
fragments containing a TpG and a cytosine to assess the
conversion. This showed .99% bisulfite conversion.
Statistical Analysis
To test for differences in maternal or child characteristics
between cases and controls, X2-, t- and Mann-Whitney U tests
were used. The mean methylation fractions presented in the tables
are based on raw data. ANOVA was used to detect possible batch-
effects of bisulphite-plate and PCR plate. For analysis of
differences in total methylation per amplicon between cases and
controls, linear mixed models were applied. Linear mixed models
were chosen as these models allow for the analyses of multiple
CpG dinucleotides in one test, account for correlation between
CpG dinucleotides, incorporate relevant adjustments within the
models and have the ability to accommodate missing data. The
REML likelihood method was used for the model fitting. DNA-
methylation was treated as a continuous variable. All models
account for the correlation between CpG dinucleotides, and
bisulphate plate number. The final analysis takes into account
potential confounding variables, including infant age and maternal
education (Dutch study) and maternal education (Texas study)
which were all entered as fixed effects. Person identifier was
entered as random effect.
Next, a possible mediating effect of DNA-methylation in the
association between maternal biomarker concentrations and NTD
risk was tested. As extended information was available of the
Dutch population, these analyses were only performed within this
study. First, we created a standard deviation score (SDS) for
maternal biomarkers levels as the absolute differences were minor.
We assessed the association between serum folate, vitamin B12
and total homocysteine (tHcy) and the occurrence of NTD using
multivariable logistic regression models. The mean MTHFR
methylation was added to the latter model to assess possible
mediation.
All tests were performed using the data measured in triplets and
all reported P-values are 2-sided. Effect sizes for NTD were
expressed in relation to the SD in the controls. To account for
multiple testing the Benjamini-Hochberg FDR correction was
used. All analyses were performed using SPSS software, version
17.0 (IBM SPSS Inc. Chicago, IL, USA).
Results
The two cohorts in this study are a Dutch case-control study
with surviving spina bifida cases, and a Texan study with both
alive and deceased spina bifida and anencephaly cases. Next to the
difference in cases of both studies the main difference is the age of
the children at investigation. The Dutch cases and controls were
investigated at the standardised age of approximately 15 months,
while the Texan study groups were investigated after pregnancy
termination or birth at the time of the Guthrie test.
The characteristics of the cases and controls are shown in
Table 1. Dutch case mothers showed a higher BMI (+2.4 kg/m2,
P-value = 0.011), a lower maternal education (20% less high
education, P-value = 0.021) and lower serum vitamin B12 levels
(286 pmol/L, P-value = 0.007) compared to control mothers.
Children with NTD had a slightly higher age at blood collection
(+0.5 y, P-value,0.001), and lower birthweight (2230 g, P-
value,0.0001) and shorter gestational age at birth (21.1 week,
P-value = 0.001) compared to controls. Whereas case mothers of
the Texan study only had a significantly higher BMI compared to
control mothers (+1.8 kg/m2, P-value = 0.035). Characteristics of
the Texan children were not available for analysis.
The mean absolute DNA-methylation in the child according to
case-control status is shown in Table 2 and Figure 1. The mean
methylation presented in Figure 1 is stratified by CpG unit, study
and case-control status. Effects and P-values in Table 2 are
corrected for CpG, bisulfite treatment plate, maternal education
(Dutch and Texan study samples) and age of the child (in the
Dutch study only). In the Dutch study, the absolute methylation of
MTHFR was 0.33% lower in case children compared to controls
(P-value = 0.001). Methylation of VANGL1 was 0.17% (P-val-
ue = 0.063) higher and of LEKR/CCNL 1.36% higher (P-
value = 0.048) in spina bifida cases as compared to controls. After
Benjamini-Hochberg correction for multiple testing only the
association with MTHFR remained significant.
In the Texan study of all six studied genes only LEKR/CCNL
showed a borderline significant association with NTD risk (effect:
20.15, P-value = 0.08), however, in the opposite direction from
the results in the Dutch study group. So, we could not replicate the
associations found in the Dutch study.
The associations between maternal biomarker concentrations
and the risk of spina bifida were tested. These analyses were
restricted to the Dutch population as these data were not available
for the Texas population. We found that for each standard
deviation increase of maternal vitamin B12 levels, a reduced risk
(adjusted OR 0.992, 95%CI: 0.99–1.00, P-value = 0.050) for NTD
was observed. Subsequently, the model was additionally adjusted
for MTHFR methylation, to test for a mediation effect. The odds
ratio was attenuated and no longer significant (adjusted OR 0.995,
95%CI: 0.99–1.00, P-value 0.27) (Table 3). However, MTHFR
methylation itself was not significant in the model (P-value = 0.77,
data not shown).
DNA-Methylation in Neural Tube Defects
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Table 1. Baseline characteristics for the two study groups.
Dutch study group Texan study group
Characteristics NTD children Control children NTD children Control children
(n=48) (n=62) P-value (n=40) (n =79) P-value
Maternal
Age at delivery (y)* 30.5 (3.9) 31.5 (3.3) NS 24.8 (6.0) 24.8 (6.1) NS
BMI (kg/m2){ 25.4 (7.5) 23.0 (4.2) 0.011 26.5 (8.1) 24.7 (7.4) 0.035
Education: high, n (%) 6 (12.8) 20 (33.3) 0.021 – – –
Education (years of school){ – – – 11 (5) 12 (4) NS
Periconceptional folic acid supplement use:
yes, n (%)
31 (66.0) 38 (63.3) NS 3 (7.5) 2 (2.6) NS
Periconceptional smoking: yes, n (%) 12 (25.5) 15 (25.0) NS 9 (22.5) 10 (12.8) NS
tHcy, plasma (mmol/L){ 10.6 (3.3) 11.1 (4.7) NS – – –
Folate, serum (nmol/L){ 16.3 (15.9) 13.4 (13.2) NS 25.4 (23.6) 22.9 (31.3) NS
Folate, RBC (nmol/L){ 780 (665) 595 (552) NS 738 (616) 824 (555) NS
Vitamin B12, serum (pmol/L){ 227 (152) 313 (184) 0.007 323 (140) 387 (162) NS
Child
Age at the study moment (y){ 1.7 (1.5) 1.2 (0.3) ,0.001 – – –
Male sex, n (%) 16 (34.0) 24 (40.0) NS – – –
Birth weight (g)* 3113 (552) 3343 (313) ,0.001 – – –
Gestational age at birth (weeks){ 38.9 (2.2) 40.0 (1.3) 0.001 – – –
tHcy, plasma (mmol/L){ 6.3 (3.1) 7.1 (1.3) NS – – –
Folate, RBC (nmol/L){ 1086 (752) 1228 (813) NS – – –
Folate, serum (nmol/L){ 31.5 (28.3) 31.0 (47.6) NS – – –
Vitamin B12, serum (pmol/L){ 503 (335) 471 (282) NS – – –
Data is presented of the Dutch study group (n = 110) and the Texan study group (n = 119). Values are presented as * mean (SD) or { median (IQR). Chi-square, t- and
Mann-Whitney U tests were used to test differences between NTD and control children.
doi:10.1371/journal.pone.0078462.t001
Table 2. Methylation in NTD and control children in the Dutch and Texan study groups.
Ncases Ncontrols Control methylation % (SD) Absolute difference P-value
Dutch children
IGF2-DMR 43 35 51.2 (22.1) +0.96 0.494
H19 43 27 26.1 (11.9) +0.62 0.333
KCNQ1OT1 41 54 38.7 (20.9) 20.21 0.886
LEKR/CCNL 46 61 2.6 (2.4) +1.36 0.048
MTHFR 47 61 1.2 (2.5) 20.33 0.001#
VANGL1 47 59 2.0 (2.9) +0.17 0.063
Texan children
IGF2-DMR 32 67 46.1 (17.9) +0.69 0.498
H19 24 50 28.2 (9.4) 20.27 0.616
KCNQ1OT1 11 22 38.4 (18.0) 20.49 0.890
LEKR/CCNL 22 48 2.5 (1.1) 20.15 0.084
MTHFR 22 48 1.2 (2.3) 20.07 0.470
VANGL1 33 78 1.9 (2.3) +0.07 0.149
Linear Mixed Model analysis.
Corrected for CpGs, bisulfite treatment plate, age of the child (Dutch children only), and maternal education.
#P,0.05 after multiple testing correction by Benjamini-Hochberg FDR.
doi:10.1371/journal.pone.0078462.t002
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Figure 1. Methylation levels per locus stratified by study and case-control status. Box and whisker plots of methylation values (y-axis) of all
individuals are shown for each CpG unit (x-axis) for NTD case and control children separately.
doi:10.1371/journal.pone.0078462.g001
Table 3. Maternal biomarker concentrations and NTD risk in offspring in the Dutch study.
NTD
aOR 95% CI P-value
Model 1: adjusted for age of the child at blood sampling, maternal educational level,
and folic acid supplement use at the moment of blood sampling
Maternal folate SDS, serum (nmol/L) 0.785 0.118–5.221 0.802
Maternal tHcy SDS, plasma (mmol/L) 1.133 0.495–2.591 0.767
Maternal vitamin B12 SDS, serum (pmol/L) 0.380 0.145–0.999 0.050
Model 2: additionally adjusted for mean MTHFR methylation
Maternal folate SDS, serum (nmol/L) 1.115 0.130–9.536 0.921
Maternal tHcy SDS, plasma (mmol/L) 1.158 0.499–2.686 0.733
Maternal vitamin B12 SDS, serum (pmol/L) 0.535 0.177–1.619 0.268
aOR, adjusted odds ratio.
Result from multivariable logistic regression analyses.
doi:10.1371/journal.pone.0078462.t003
DNA-Methylation in Neural Tube Defects
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Discussion
In this combined study of a Dutch and a Texan case-control
study, we found in the Dutch study group an association of DNA-
methylation levels of the MTHFR CpG-island with NTD in
children. In addition, our results suggest mediation of MTHFR
methylation in the association between maternal vitamin B12 and
spina bifida in offspring. This association was not observed in the
Texan study group. We did not find significant associations for the
imprinted IGF2 DMR, H19, and KCNQ1OT1 genes or for the non-
imprinted genes VANGL1 and LEKR/CCNL after correction for
multiple testing.
The role of the folate dependent 1-C metabolism in the etiology
of NTD has been consistently shown. Maternal hyperhomocys-
teinemia as a sensitive marker of a deranged 1-C metabolism has
been associated with an increased risk of NTD in the offspring
[12,40,41]. One of the proposed underlying mechanisms of this
association is the induction of alterations in DNA-methylation of
genes implicated in embryonic and neural tube development.
DNA methyltransferases (DNMTs) use methyl donors from the 1-
C metabolism to establish and maintain DNA-methylation [42].
Disruption of DNMT3b in animal models, which is responsible for
de novo methylation, resulted in NTD [22], which supports DNA-
methylation as possible mechanism in the causation of NTD. A
key gene within the 1C-metabolism is MTHFR. Common variants
of the MTHFR gene have been shown to be also associated with
NTD risk [9,20]. The combined heterozygozity of these two
polymorphisms resulted in reduced activity of the enzyme and was
associated with NTD [17]. In the present study, we found a small
difference but significantly lowerMTHFR DNA-methylation levels
in Dutch children with spina bifida. Lower DNA-methylation
levels could indicate higher activity of the gene, which would
suggest an opposite effect from the study by Van den Put et al.,
where lower activity of the gene was associated with higher NTD
risk [17]. Because we conducted a cross-sectional study we cannot
distinguish whether the observed association is a cause or outcome
of NTD. The samples in the Dutch study were drawn around 15
months after birth. Therefore, we cannot exclude an environ-
mental or disease-driven effect on the DNA-methylation levels of
MTHFR in these children.
The Dutch NTD have previously been associated with higher
zinc, glutamine, lower glucose, and creatinine concentrations in
amniotic fluid of the children [43,44], and with higher glucose,
lower zinc, myo-inositol and vitamin B12 concentrations in the
mothers [6,27,45]. The lower maternal B12 concentrations in
cases could lead to a derangement of 1C-metabolism, which could
have effected DNA-methylation levels of MTHFR in the children.
This could indicate that the lower MTHFR DNA-methylation
level is implicated in the causative pathway of the development of
NTDs. Nevertheless, MTHFR methylation was not significant in
the mediation model. This could be due to the relatively small
sample size of our study, so additional studies are warranted to
confirm these results.
While we do not observe any association of H19 with NTDs in
blood of these subjects, a recent study in brain tissue of Chinese
NTD cases and controls showed a significant decrease in H19-
DMR1 DNA-methylation in cases [46]. One of the reasons that
we find different results for H19 DNA-methylation in association
with NTDs is that we studied a different region 59of the H19 gene.
Liu et al. studied a region located around 2 kb upstream of the
gene, while the region we studied was located 300–700 bp 59of the
gene. Methylation at different regions at a locus could show
uncorrelated results.
Some strengths and limitations of this study have to be
addressed. Our study is the first to investigate DNA-methylation
levels in peripheral white blood cells in relation to the occurrence
of NTD in children. Previous studies on DNA-methylation levels
in NTD studied DNA-methylation in brain tissue, but neither
candidate gene nor global DNA-methylation in white blood cells
[24–26]. In the present study we were not able to study brain tissue
of NTD cases and controls, and therefore we are not sure if DNA
methylation status of white blood cells is an appropriate surrogate
for that of brain tissues during development. In particular, there is
a possibility that the differences in DNA-methylation could be
attributed to the cellular heterogeneity in leukocytes. Nonetheless,
the ENCODE project showed recently that CpGs in promoters
and upstream regulatory regions display less variation between cell
types and tissues compared to CpGs in gene bodies and intergenic
regions [47]. In the present study we have mainly focused on
CpGs in CpG-islands in the promoter and upstream regions of the
genes. Therefore, we expect that the levels we measure in whole
blood are similar to those in brain tissue, or at least that the levels
show moderate to good correlation. It remains unclear to what
extend our results in white blood cells are comparable to brain
tissue. However, it is impossible to perform these studies on human
brain tissue in similar cases and controls. Although it is difficult to
generalize our results, they might give us a clue to what genes are
epigenetically involved in the development of NTDs.
Another strength of our study is that with the EpiTYPER
method we have covered a great part of the CpG-island in the
promoter or regulatory region of each gene, so we have conducted
a very thorough search for the candidate genes we selected.
Furthermore, we have compared data for two independent studies
for the association of DNA-methylation with NTD, although we
could not replicate our findings.
One of the limitations is the relative small control group for
both the Dutch and the Texas study. For the most optimal power
one would need 3 controls for each case and we only had one to
two controls per case. However, based on previous studies we
assume the effect of small DNA-methylation differences to be
relatively large [5]. So we expect to identify true significant
associations with our sample size and case:control ratio. The blood
of the Texan study was obtained at the time of the Guthrie test,
shortly after birth or after pregnancy termination while the blood
of the Dutch study was obtained 15 months after birth. Therefore,
due to this time difference we could not combine the Dutch and
the Texas study samples, because we assume the 15 months
difference in age to have an effect on the DNA-methylation levels
of the children. Also, the Dutch cases are all spina bifida cases
surviving one year of age, while the Texas samples include both
spina bifida and anencephaly cases of which not all were survivors.
For genetic variation it is well known that a different ethnic
background could influence the linkage disequilibrium and
therefore the association with outcomes. This is not known for
epigenetic variations, which we could not study in our study
populations.
A technical limitation of this study is the sensitivity of the
method we have used to detect DNA-methylation levels. It is
known for the MassARRAY technique that this is around 5%,
while part of our results are lower than this. Therefore, additional
studies using a different technique are needed to validate the
observed association of MTHFR DNA-methylation with the risk
for NTDs.
Lastly, we performed a candidate gene approach to investigate
the effect of DNA-methylation in association with NTD, however,
the evidence based selected genes may not be the main genes
involved in NTD. So, we might have missed DNA-methylation
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differences between cases and control in other more important
genes. To circumvent this, a hypothesis-free epigenome-wide
association approach should be followed. However, this requires
ample amounts of DNA, and because we studied DNA of children
we did not obtain enough DNA from the small amounts of blood
to perform these experiments in the present study.
This study was the first to investigate DNA-methylation levels of
several imprinted and non-imprinted candidate genes in WBC in
association with NTD. We observed a small but significant
association of MTHFR methylation levels with NTD, which could
support a potential functional link between 1C-metabolism and
NTDs. This link should be investigated in other studies and more
in depth in animal studies for example in order to establish
causality of lower MTHFR DNA-methylation in NTD.
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